<DOC>
	<DOCNO>NCT00270647</DOCNO>
	<brief_summary>The use vitamin E , vitamin C , beta carotene , and/or multivitamin may keep cancer , cardiovascular disease , eye disease , cognitive decline occur . This randomized clinical trial study vitamin E , vitamin C , beta carotene , and/or multivitamin see well work compare placebo prevent cancer , cardiovascular disease , eye disease , cognitive decline male doctor age 50 year old .</brief_summary>
	<brief_title>Physicians ' Health Study II</brief_title>
	<detailed_description>OBJECTIVES : Primary - To determine whether vitamin E every day reduce risk develop prostate cancer old healthy male physician . - To determine whether daily vitamin C and/or multivitamin reduces risk total cancer participant . - To determine whether vitamin E every day , vitamin C daily , multivitamin daily reduces risk major cardiovascular event participant . Secondary - To determine whether vitamin E and/or multivitamin reduce risk develop total cancer , colon cancer , colon polyp participant . - To determine whether vitamin E , vitamin C , multivitamins reduce risk myocardial infarction stroke participant . - To determine whether vitamin E , vitamin C , multivitamins reduce risk age-related macular degeneration cataract participant . - To determine whether vitamin E , vitamin C , multivitamins reduce risk early cognitive decline participant age 65 . The Physicians ' Health Study II randomize , double-blind , placebo-controlled , factorial trial begin 1997 end 2011 . It design test four supplement -- ( 1 ) alternate-day vitamin E ( 400 international unit synthetic alpha-tocopherol ) placebo ; ( 2 ) daily vitamin C ( 500 mg synthetic ascorbic acid ) placebo ; ( 3 ) daily multivitamin ( Centrum Silver ) placebo ; ( 4 ) alternate-day beta carotene ( 50 mg Lurotin ) placebo -- prevention cancer , cardiovascular disease , eye disease , early cognitive decline among 14,641 male physician age 50 year old . Participants randomly assign 2x2x2x2 factorial trial receive combination four active supplement placebo . Pills and/or packaging provide BASF Corporation , Pfizer ( formerly Wyeth , American Home Products , Lederle ) , DSM Nutritional Products ( formerly Roche Vitamins ) . The beta-carotene component discontinue March 8 , 2003 ; vitamin E vitamin C component end schedule August 31 , 2007 ; multivitamin component end June 1 , 2011 .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Cardiovascular Diseases</mesh_term>
	<mesh_term>Eye Diseases</mesh_term>
	<mesh_term>Cognition Disorders</mesh_term>
	<mesh_term>Vitamins</mesh_term>
	<mesh_term>Vitamin E</mesh_term>
	<mesh_term>Tocopherols</mesh_term>
	<mesh_term>Tocotrienols</mesh_term>
	<mesh_term>alpha-Tocopherol</mesh_term>
	<mesh_term>Ascorbic Acid</mesh_term>
	<mesh_term>Beta Carotene</mesh_term>
	<mesh_term>Carotenoids</mesh_term>
	<criteria>INCLUSION CRITERIA 1 . DISEASE CHARACTERISTICS : Healthy male physician practice United States Prior participation Physicians ' Health Study I allow 2 . PATIENT CHARACTERISTICS : Aged 50 year No history serious illness would preclude study participation No history significant adverse event ( e.g. , rash allergic reaction ) attribute study agent 3 . PRIOR CONCURRENT THERAPY : No concurrent vitamin and/or multivitamin supplementation No concurrent vitamin Kdepleting anticoagulant ( e.g. , warfarin )</criteria>
	<gender>Male</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2012</verification_date>
	<keyword>cancer</keyword>
	<keyword>prostate cancer</keyword>
	<keyword>colorectal cancer</keyword>
	<keyword>cardiovascular disease</keyword>
	<keyword>eye disease</keyword>
	<keyword>cognitive decline</keyword>
</DOC>